Many studies with a stated goal of advancing child health care in administratively-defined minors have no clinical value and may even harm young patients.
Imposing the FDA on-label/off-label framework on administratively defined "children" resulted in a regulatory demand for pediatric studies that had no basis in clinical medicine, with the exception of the small group of preterm newborns.